5.9 Brugada Syndrome Brugada Syndrome ECG characteristics: Etiology: Genetic defects with up to three mutations in SCN5A (sodium channel) with frequent familial occurrence of ventricular fibrillation ECG characteristics: Three types of repolarisation patterns: Type 1: “tentlike” coved ST-segment elevation displaying a “J-wave” amplitude or elevated ST-segment≥0.2 mVin V1-2 (V3), negative T wave Type 2: “saddle back”-configuration of ST-segment elevation ≥ 0.1 mV, positive T wave Type 3: “saddle back”-configuration of ST-segment elevation ≤ 0.1 mV, positive T wave exaggeration or unmasking after drug challenging (ajmaline, flecainide, procainamid) Occurrence of malignant ventricular arrhythmias (in particular ventricular fibrillation) Treatment: No specific treatment of the underlying disease Debrillator insertion with malignant ventricular arrhythmias (syncope, post cardiac resuscitation) Monitoring of family members Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: The Isthmus Region Acute Pulmonary Embolism Supraventricular Extrasystole Medication-Related ECG Changes Stay updated, free articles. Join our Telegram channel Join Tags: Easy ECG Aug 29, 2016 | Posted by admin in CARDIOLOGY | Comments Off on Brugada Syndrome Full access? Get Clinical Tree
5.9 Brugada Syndrome Brugada Syndrome ECG characteristics: Etiology: Genetic defects with up to three mutations in SCN5A (sodium channel) with frequent familial occurrence of ventricular fibrillation ECG characteristics: Three types of repolarisation patterns: Type 1: “tentlike” coved ST-segment elevation displaying a “J-wave” amplitude or elevated ST-segment≥0.2 mVin V1-2 (V3), negative T wave Type 2: “saddle back”-configuration of ST-segment elevation ≥ 0.1 mV, positive T wave Type 3: “saddle back”-configuration of ST-segment elevation ≤ 0.1 mV, positive T wave exaggeration or unmasking after drug challenging (ajmaline, flecainide, procainamid) Occurrence of malignant ventricular arrhythmias (in particular ventricular fibrillation) Treatment: No specific treatment of the underlying disease Debrillator insertion with malignant ventricular arrhythmias (syncope, post cardiac resuscitation) Monitoring of family members Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: The Isthmus Region Acute Pulmonary Embolism Supraventricular Extrasystole Medication-Related ECG Changes Stay updated, free articles. Join our Telegram channel Join